In the Virtual Courtroom: Cross-Examination/Impeaching a Witness

on May 3, 2022

“Commercially Reasonable Efforts” Clauses in Drug Development Deals: What Level of Protection Do They Really Provide?

From Proskauer in Life Sciences Blog on July 13, 2021

Synthetic Data Gets Real

From Proskauer in Life Sciences Blog on June 29, 2021

The Impact of the Ensuring Innovation Act on NCE Exclusivity

From Proskauer in Life Sciences Blog on April 28, 2021

Weekend Read | Reopening Colleges Will Disproportionately Harm Workers of Color

“Legal Battles Extend to Failures in Drug Development” by Colin Cabral is highlighted as a top weekend read.

From Bloomberg Law on June 27, 2020

INSIGHT: Legal Battles Extend to Failures in Drug Development

Colin Cabral authored a piece on drug development, strategic considerations and practical guidance relating to potential legal disputes arising out of unsuccessful development.

From Bloomberg Law on June 23, 2020

Investors Say Shire Tried to Spin Free of $45M Merger Tab

The Firm, Timothy Mungovan, Colin Cabral, Michael Hackett, James Anderson and Alexandra Bargoot are noted for representing Shire Holdings and Shire Pharmaceuticals. Tim and Colin are also quoted in the article.

From Law360 on March 2, 2020

Proskauer Honors Pro Bono Work at Tenth Annual Golden Gavels

on January 16, 2018

Amgen, Genentech Await Delaware Ruling in Biosimilar IP Row

Sige Gutman, Steve Bauer, Colin Cabral, Thomas Chen, Graham Cole and Christine Nam are noted for representing Amgen in Amgen Inc. v. Genentech Inc. et al. Remarks made by Sige in court are quoted.

From Law360 on January 12, 2018

Proskauer Litigators Recognized in 2018 Benchmark Litigation Guide

on October 19, 2017